BACKGROUND: The rate of adverse events after pancreatectomy is widely reported as a measure of surgical quality. However, morbidity data are routinely acquired retrospectively and often are reported at 30 days. The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy. METHODS: The authors instituted an active surveillance system to detect, categorize, and grade the severity of all adverse events after pancreatectomy, using the modified Accordion system and International Study Group of Pancreatic Surgery definitions. All patients and clinical events were monitored directly for at least 90 days after surgery. RESULTS: Of 315 consecutively monitored patients, 239 (76 %) experienced 500 unique adverse events. The absolute number of unique adverse events increased by 32 % between index discharge and 90 days and by 10 % between 30 and 90 days. The number of severe adverse events increased by 96 % between discharge and 90 days and by 29 % between 30 and 90 days. In this study, 16 % of the patients experienced at least one severe adverse event within the index hospitalization, 24 % within 30 postoperative days, and 29 % within 90 days. Among the 80 readmissions that occurred within 90 days, 28 (35 %) occurred later than 30 days after pancreatectomy. CONCLUSIONS: Approximately one-third of severe adverse events and readmissions are reported more than 30 days after surgery. All adverse events that occur within 90 days of surgery must be identified and reported for accurate characterization of the morbidity associated with pancreatectomy.
BACKGROUND: The rate of adverse events after pancreatectomy is widely reported as a measure of surgical quality. However, morbidity data are routinely acquired retrospectively and often are reported at 30 days. The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy. METHODS: The authors instituted an active surveillance system to detect, categorize, and grade the severity of all adverse events after pancreatectomy, using the modified Accordion system and International Study Group of Pancreatic Surgery definitions. All patients and clinical events were monitored directly for at least 90 days after surgery. RESULTS: Of 315 consecutively monitored patients, 239 (76 %) experienced 500 unique adverse events. The absolute number of unique adverse events increased by 32 % between index discharge and 90 days and by 10 % between 30 and 90 days. The number of severe adverse events increased by 96 % between discharge and 90 days and by 29 % between 30 and 90 days. In this study, 16 % of the patients experienced at least one severe adverse event within the index hospitalization, 24 % within 30 postoperative days, and 29 % within 90 days. Among the 80 readmissions that occurred within 90 days, 28 (35 %) occurred later than 30 days after pancreatectomy. CONCLUSIONS: Approximately one-third of severe adverse events and readmissions are reported more than 30 days after surgery. All adverse events that occur within 90 days of surgery must be identified and reported for accurate characterization of the morbidity associated with pancreatectomy.
Authors: Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2016-10-11 Impact factor: 3.452
Authors: Emily Z Keung; Elliot A Asare; Yi-Ju Chiang; Laura R Prakash; Nikita Rajkot; Keila E Torres; Kelly K Hunt; Barry W Feig; Janice N Cormier; Christina L Roland; Matthew H G Katz; Jeffrey E Lee; Ching-Wei D Tzeng Journal: Am J Surg Date: 2019-11-30 Impact factor: 2.565
Authors: Jason W Denbo; Morgan Bruno; Whitney Dewhurst; Michael P Kim; Ching-Wei Tzeng; Thomas A Aloia; Jose Soliz; Barbara Bryce Speer; Jeffrey E Lee; Matthew H G Katz Journal: Surgery Date: 2018-05-25 Impact factor: 3.982
Authors: Jason W Denbo; Rebecca S Slack; Morgan Bruno; Jordan M Cloyd; Laura Prakash; Jason B Fleming; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz Journal: J Gastrointest Surg Date: 2017-01-03 Impact factor: 3.452
Authors: Timothy P DiPeri; Timothy E Newhook; Laura R Prakash; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng Journal: J Surg Oncol Date: 2022-06-20 Impact factor: 2.885
Authors: Russell G Witt; Timothy E Newhook; Laura R Prakash; Morgan L Bruno; Elsa M Arvide; Whitney L Dewhurst; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng Journal: J Surg Res Date: 2022-03-17 Impact factor: 2.417
Authors: Scott Kizy; Ariella M Altman; Keith M Wirth; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Emil Lou; Khalid Amin; Jason W Denbo; Eric H Jensen Journal: Hepatobiliary Surg Nutr Date: 2020-06 Impact factor: 7.293
Authors: Casey J Allen; Nikhil G Thaker; Laura Prakash; Brittany C Kruse; Thomas W Feeley; Robert S Kaplan; Ryan Huey; Steven J Frank; Thomas A Aloia; Vijaya Gottumukkala; Matthew H G Katz Journal: Ann Surg Date: 2021-01-01 Impact factor: 13.787
Authors: Jose M Soliz; Ifeyinwa C Ifeanyi; Mathew H Katz; Jonathan Wilks; Juan P Cata; Thomas McHugh; Jason B Fleming; Lei Feng; Thomas Rahlfs; Morgan Bruno; Vijaya Gottumukkala Journal: Anesth Pain Med Date: 2017-08-21